Atorvastatin Interactions with Other Medicines
Atorvastatin is one of the most prescribed medicines in the UK, used to lower cholesterol and reduce the risk of heart attack and stroke. It is effective and generally well tolerated, but it can interact with other medicines, foods and even some supplements, sometimes increasing the risk of serious muscle damage. The editorial team sets out the interactions worth knowing about.
How atorvastatin is processed in the body
Atorvastatin works by blocking HMG-CoA reductase, a liver enzyme essential for making cholesterol. Lower cholesterol production prompts liver cells to remove more LDL ("bad") cholesterol from the blood. NICE recommends atorvastatin as the first-choice statin for both primary and secondary prevention of cardiovascular disease.
The drug is metabolised mainly by the liver enzyme CYP3A4. It is also transported into liver cells by a carrier protein called OATP1B1 and pumped out of cells by other transporters. Any medicine that blocks these pathways can raise atorvastatin levels in the blood, while medicines that speed them up can lower its effect.
Why does this matter? The most important dose-related side effect of statins is muscle toxicity. This ranges from muscle aches (myalgia) to myopathy with raised creatine kinase (CK) and, very rarely, rhabdomyolysis, a breakdown of muscle tissue that can cause kidney failure. Higher blood levels of the statin increase this risk.
Not all statins share the same profile. Pravastatin and rosuvastatin are less dependent on CYP3A4, so a doctor may switch to one of these when a patient needs a medicine that interacts with atorvastatin.
Medicines that raise atorvastatin levels
Strong CYP3A4 inhibitors and certain transporter blockers are the most significant interacting drugs. The table summarises key examples cited in UK prescribing information and pharmacology reviews.
| Medicine or group | Mechanism | Typical management |
|---|---|---|
| Clarithromycin, erythromycin | CYP3A4 inhibition | Often pause the statin during the antibiotic course |
| Itraconazole, ketoconazole, posaconazole | Strong CYP3A4 inhibition | Avoid combination or pause statin |
| HIV and hepatitis C protease inhibitors | CYP3A4 and transporter inhibition | Specialist dose limits or alternative statin |
| Ciclosporin | Transporter (OATP1B1) inhibition | Combination generally avoided |
| Gemfibrozil | Interferes with statin handling; additive muscle risk | Avoid; other fibrates used with caution |
| Diltiazem, verapamil | Moderate CYP3A4 inhibition | Lower statin dose may be considered |
| Fusidic acid (systemic) | Serious rhabdomyolysis reports | Stop statin during treatment and for 7 days after |
| Colchicine | Additive muscle toxicity | Monitor for muscle symptoms |
Fusidic acid deserves special emphasis. The MHRA has warned that systemic fusidic acid (tablets or infusion) should not be given with statins, because of reports of rhabdomyolysis, some fatal. The statin should be stopped during treatment and restarted only seven days after the last dose of fusidic acid. Topical fusidic acid creams do not carry the same risk.
Clarithromycin is another everyday example. It is commonly prescribed for chest and throat infections, and many GPs advise patients to pause atorvastatin while taking it. Missing a statin for a week has negligible effect on long-term cardiovascular risk.
Medicines that lower its effect and other relevant interactions
Some medicines induce CYP3A4, speeding up the breakdown of atorvastatin and potentially reducing its cholesterol-lowering effect. Examples include rifampicin, carbamazepine, phenytoin and the herbal remedy St John's wort.
Rifampicin is a particular case: if taken at the same time as atorvastatin, it can briefly increase levels by blocking uptake transporters, whereas taken at different times its enzyme-inducing effect lowers levels. This complexity is a good example of why interactions are best managed by a pharmacist.
- Warfarin: starting atorvastatin may slightly change INR; monitoring is advised.
- Digoxin: atorvastatin can modestly raise digoxin levels.
- Oral contraceptives: atorvastatin may increase hormone levels slightly; not usually clinically significant.
- Ticagrelor: may raise atorvastatin exposure; generally acceptable with monitoring.
- Ezetimibe: commonly combined deliberately for additional LDL lowering.
Combining atorvastatin with ezetimibe or, in specialist settings, with PCSK9 inhibitors is a planned therapeutic strategy rather than a problematic interaction. These combinations are used when a single statin does not achieve the target reduction in LDL cholesterol.
Grapefruit, alcohol and supplements
Grapefruit juice inhibits CYP3A4 in the gut wall and can raise blood levels of atorvastatin. The NHS advises people on atorvastatin to avoid drinking large amounts of grapefruit juice. Occasional small quantities are unlikely to be a problem, but daily large glasses should be avoided.
Alcohol does not interact directly in a pharmacokinetic sense, but heavy drinking adds to the risk of liver problems and muscle damage. Staying within the UK low-risk guidelines of no more than 14 units per week spread over several days is advisable.
Red yeast rice is a supplement that naturally contains monacolin K, chemically identical to lovastatin. Taking it alongside atorvastatin effectively doubles up statin therapy and increases the risk of side effects. The two should not be combined.
Coenzyme Q10 is often taken in the hope of preventing statin muscle aches. Its effects in trials have been inconsistent, but it does not appear to interact harmfully. Niacin at high doses can add to muscle and liver risks and is rarely used now.
Atorvastatin and training: what athletes should know
Many active adults take statins, including masters athletes. Intense, unaccustomed exercise itself raises creatine kinase and can cause muscle soreness, which can make it harder to distinguish normal training effects from statin-related problems.
Signs that warrant urgent medical attention include severe, unexplained muscle pain or weakness, especially with dark, cola-coloured urine, fever or feeling generally unwell. These may indicate rhabdomyolysis, which requires immediate assessment.
Before a blood test that includes CK, it is wise to avoid strenuous exercise for several days and to tell the doctor about recent training. Otherwise, a high CK may lead to unnecessary changes in treatment.
Athletes should never stop a prescribed statin on their own because of performance concerns. If muscle symptoms appear, a GP can review the dose, check for interacting medicines and consider switching to a different statin.
Conclusions of the editorial team
Atorvastatin is metabolised by CYP3A4 and transported by OATP1B1, which explains most of its interactions. Drugs that block these pathways raise its levels and the risk of muscle damage.
Key combinations to avoid or manage include clarithromycin, azole antifungals, HIV protease inhibitors, ciclosporin, gemfibrozil and systemic fusidic acid. Large amounts of grapefruit juice and red yeast rice should also be avoided.
Active people on statins should be aware of muscle symptoms, inform doctors about training before CK tests, and discuss any problems rather than stopping treatment.
The editorial team also recommends our articles on interpreting creatine kinase after training, on lipid profiles in athletes, and on coenzyme Q10 supplementation.
References
- Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–e495.
- Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–581.
- Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141–1160.
- Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238). London: NICE; 2023.
- Medicines and Healthcare products Regulatory Agency. Systemic fusidic acid: interaction with statins. Drug Safety Update. London: MHRA.
